Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.40 |
| ▸ | KRAS | P01116 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31217104 | 1.00 | PIK3CA (0.45) | PIK3CAMTORPIK3CDPIK3R1KRAS | |
| SCHEMBL31217127 | 0.88 | PIK3CA (0.38) | PIK3CAPIK3CDPIK3R1 | |
| SCHEMBL23909775 | 0.88 | PIK3CA (0.38) | PIK3CAPIK3CDPIK3R1 | |
| SCHEMBL21662916 | 0.87 | KRAS (0.50) | KRAS | |
| SCHEMBL31217079 | 0.87 | KRAS (0.50) | KRAS | |
| SCHEMBL21662774 | 0.84 | KRAS (0.52) | KRAS | |
| SCHEMBL31217096 | 0.84 | KRAS (0.54) | KRAS | |
| SCHEMBL23909739 | 0.84 | KRAS (0.54) | KRAS | |
| SCHEMBL23909751 | 0.81 | KRAS (0.40) | PIK3CAMTORPIK3CDKRAS | |
| SCHEMBL31217209 | 0.81 | KRAS (0.40) | PIK3CAMTORPIK3CDKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | PIK3CA 134/4885MTOR 303/4885PIK3CD 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.